---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-002338"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-07-22T23:59:59+00:00"
generated_at: "2026-06-30T03:18:47.065542+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Chemomab Therapeutics Shareholders Approve Compensation, CEO Terms, Share Plan, and Auditor at 2021 Meeting

## Summary
- Proposal 1: Compensation Policy approved with 103,259,980 votes for (99.5%), meeting Israeli Companies Law requirements for non-controlling shareholders.
- Proposal 2: Amendment to CEO Dr. Adi Mor's engagement terms approved with 103,495,100 votes for (99.7%), satisfying requisite majority.
- Proposal 3: Share incentive plan increase by 540,000 ADSs (10,800,000 ordinary shares) approved with 103,184,280 votes for.
- Proposal 4: Reappointment of Somekh Chaikin (KPMG) as independent auditors approved with 103,862,300 votes for.

## SEC filing metadata
- accession: 0001178913-21-002338
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-07-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002338/0001178913-21-002338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002338/zk2126316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-002338
- JSON: https://secwatch.observer/filing/0001178913-21-002338.json
- Plain text: https://secwatch.observer/filing/0001178913-21-002338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.